OSLO, Norway, May 03 2021 – LINK Medical, the Northern European clinical research organization (CRO), today announced the expansion of its regulatory team with the recent appointment of new regulatory directors in Norway, Sweden and Denmark. This growth further builds upon the company’s existing capabilities in early development regulatory strategies including Investigational Medicinal Product Dossiers (IMPD), particularly focused on the Chemistry, Manufacturing and Controls (CMC) section. The strengthened capabilities introduced by these new directors assist companies in achieving compliance with EU regulations that ensure clinical trial approval and patient safety.
The regulatory team offers strong expertise that supports customers within the early clinical development stages. This includes regulatory strategies, GAP analysis, IMPD and CMC support, both for biologicals and non-biologicals, – The appointment of new regulatory directors enables LINK Medical to build an even st